NXTC insider transaction filings
NextCure, Inc. — 47 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-12. Screen NXTC transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 3 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 13 legs across 2 filings by 2 insiders — 346,761 shares, $1,711,833 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 1 leg across 1 filing by 6 insiders — 30,000 shares, $184,800 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: purchase of 100,000 shares @ $4.90 ($490,000) by ADAR1 Capital Management, LLC, filed 2026-08-03.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| ADAR1 Capital Management, LLC — 10% owner & Schneeberger Daniel — 10% owner | 2 | 13 legs · 346,761 sh · $1,711,833 | — | — |
| Simcere Zaiming, Inc. & Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. & Simcere Zaiming Pharmaceutical Co., Ltd. & Simcere Pharmaceutical Group Ltd & Ren Jinsheng & Tang Renhong | 1 | — | 1 leg · 30,000 sh · $184,800 | — |
Recent Form 4 filings — NextCure, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-12 | 4 | Simcere Zaiming, Inc. Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. Simcere Zaiming Pharmaceutical Co., Ltd. Simcere Pharmaceutical Group Ltd Ren Jinsheng Tang Renhong | Sale (S): 30,000 @ $6.16 | EDGAR |
| 2026-08-03 | 4 | ADAR1 Capital Management, LLC — 10% owner Schneeberger Daniel — 10% owner | Purchase (P): 50,000 @ $4.97 · Purchase (P): 20,000 @ $5 · Purchase (P): 20,000 @ $5 · Purchase (P): 25,000 @ $4.81 · Purchase (P): 100,000 @ $4.90 · Purchase (P): 77,850 @ $4.96 · +3 more | EDGAR |
| 2026-07-29 | 4 | ADAR1 Capital Management, LLC — 10% owner Schneeberger Daniel — 10% owner | Purchase (P): 7,798 @ $5.00 · Purchase (P): 6,400 @ $4.95 · Purchase (P): 1,810 @ $5 · Purchase (P): 1,600 @ $5 | EDGAR |
| 2026-06-22 | 4 | Borgman Anne Elizabeth — Director | Grant/award (A): 2,340 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Feigal Ellen — Director | Grant/award (A): 2,340 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Houston John G — Director | Grant/award (A): 2,340 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Webster Stephen W — Director | Grant/award (A): 2,340 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Jones Elaine V — Director | Grant/award (A): 2,340 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | KABAKOFF DAVID S — Director | Grant/award (A): 3,510 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Shaw Kevin G. — Sr VP, General Counsel | Grant/award (A): 8,270 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Kundu Sourav — Sr VP, Dev. & Mfg. | Grant/award (A): 8,270 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Mayer Timothy — Chief Operating Officer | Grant/award (A): 14,670 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Guha Udayan — Chief Medical Officer | Grant/award (A): 14,670 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Cobourn Steven P. — Chief Financial Officer | Grant/award (A): 14,670 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Richman Michael — President & CEO, Director | Grant/award (A): 38,190 (derivative) @ $0 | EDGAR |
| 2025-06-24 | 4 | Houston John G — Director | Grant/award (A): 18,700 (derivative) @ $0 | EDGAR |
| 2025-06-24 | 4 | Borgman Anne Elizabeth — Director | Grant/award (A): 18,700 (derivative) @ $0 | EDGAR |
| 2025-06-24 | 4 | Feigal Ellen — Director | Grant/award (A): 18,700 (derivative) @ $0 | EDGAR |
| 2025-06-24 | 4 | Webster Stephen W — Director | Grant/award (A): 18,700 (derivative) @ $0 | EDGAR |
| 2025-06-24 | 4 | Jones Elaine V — Director | Grant/award (A): 18,700 (derivative) @ $0 | EDGAR |
| 2025-06-24 | 4 | KABAKOFF DAVID S — Director | Grant/award (A): 28,050 (derivative) @ $0 | EDGAR |
| 2025-02-03 | 4 | Shaw Kevin G. — Sr VP, General Counsel | Grant/award (A): 66,125 (derivative) @ $0 | EDGAR |
| 2025-02-03 | 4 | Mayer Timothy — Chief Operating Officer | Grant/award (A): 117,375 (derivative) @ $0 | EDGAR |
| 2025-02-03 | 4 | Langermann Sol — Chief Scientific Officer | Grant/award (A): 117,375 (derivative) @ $0 | EDGAR |
| 2025-02-03 | 4 | Kundu Sourav — Sr VP, Dev. & Mfg. | Grant/award (A): 66,125 (derivative) @ $0 | EDGAR |
| 2025-02-03 | 4 | Cobourn Steven P. — Chief Financial Officer | Grant/award (A): 117,375 (derivative) @ $0 | EDGAR |
| 2025-02-03 | 4 | Richman Michael — President & CEO, Director | Grant/award (A): 305,500 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Houston John G — Director | Grant/award (A): 18,700 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Feigal Ellen — Director | Grant/award (A): 18,700 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Borgman Anne Elizabeth — Director | Grant/award (A): 18,700 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Webster Stephen W — Director | Grant/award (A): 18,700 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Jones Elaine V — Director | Grant/award (A): 18,700 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | KABAKOFF DAVID S — Director | Grant/award (A): 28,050 (derivative) @ $0 | EDGAR |
| 2024-04-02 | 4 | Shaw Kevin G. — Sr VP, General Counsel | Grant/award (A): 93,900 (derivative) @ $0 | EDGAR |
| 2024-04-02 | 4 | Myint Han — Chief Medical Officer | Grant/award (A): 93,900 (derivative) @ $0 | EDGAR |
| 2024-04-02 | 4 | Mayer Timothy — Chief Operating Officer | Grant/award (A): 93,900 (derivative) @ $0 | EDGAR |
| 2024-04-02 | 4 | Langermann Sol — Chief Scientific Officer | Grant/award (A): 93,900 (derivative) @ $0 | EDGAR |
| 2024-04-02 | 4 | Kundu Sourav — Sr VP, Dev. & Mfg. | Grant/award (A): 52,900 (derivative) @ $0 | EDGAR |
| 2024-04-02 | 4 | Cobourn Steven P. — Chief Financial Officer | Grant/award (A): 93,900 (derivative) @ $0 | EDGAR |
| 2024-04-02 | 4 | Richman Michael — President & CEO, Director | Grant/award (A): 244,400 (derivative) @ $0 | EDGAR |
| 2024-02-01 | 4 | Shaw Kevin G. — Sr VP, General Counsel | Grant/award (A): 66,125 (derivative) @ $0 | EDGAR |
| 2024-02-01 | 4 | Myint Han — Chief Medical Officer | Grant/award (A): 117,375 (derivative) @ $0 | EDGAR |
| 2024-02-01 | 4 | Mayer Timothy — Chief Operating Officer | Grant/award (A): 117,375 (derivative) @ $0 | EDGAR |
| 2024-02-01 | 4 | Langermann Sol — Chief Scientific Officer | Grant/award (A): 117,375 (derivative) @ $0 | EDGAR |
| 2024-02-01 | 4 | Kundu Sourav — Sr VP, Dev. & Mfg. | Grant/award (A): 66,125 (derivative) @ $0 | EDGAR |
| 2024-02-01 | 4 | Cobourn Steven P. — Chief Financial Officer | Grant/award (A): 117,375 (derivative) @ $0 | EDGAR |
| 2024-02-01 | 4 | Richman Michael — President & CEO, Director | Grant/award (A): 305,500 (derivative) @ $0 | EDGAR |
Recent 8-K events — NextCure, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement ? 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-25 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-01 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-23 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-19 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-17 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=NXTC returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →